Why Has Model‐Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future
Year: 2017
Type: review
Abstract: Patient groups prone to polypharmacy and special subpopulations are susceptible to suboptimal treatment. Refined dosing in special populations is imperative to improve therapeutic response and/or lowering the risk of toxicity. Model-informed precision dosing (MIPD) may improve treatment outcomes by achieving the optimal dose for an individual patient. There is, however, relatively little published evidence of large-scale utility and impact of MIPD, where it is often implemented as local collaborative efforts between academia and healthcare. This article highlights some successful applications of bringing MIPD to clinical care and proposes strategies for wider integration in healthcare. Considerations are brought up herein that will need addressing to see MIPD become "widespread clinical practice," among those, wider interdisciplinary collaborations and the necessity for further evidence-based efficacy and cost-benefit analysis of MIPD in healthcare. The implications of MIPD on regulatory policies and pharmaceutical development are also discussed as part of the roadmap.
DOI: 10.1002/cpt.659
Institutions: University of Manchester, Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of North Carolina at Chapel Hill, University of Geneva, University Hospital of Geneva, GlaxoSmithKline (United Kingdom), Pfizer (United States), University of Florida, University of Washington, Fred Hutch Cancer Center, Leiden University, St. Antonius Ziekenhuis, Radboud University Nijmegen, Erasmus MC - Sophia Children’s Hospital, Children's Mercy Hospital, University of Missouri–Kansas City, University of Southern California, Children's Hospital Los Angeles, Children's Hospital of Philadelphia
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Pfizer, Medical Research Council
Award: G2023605512
OpenAlex ID: W2587355458
